New research from investigators at the Johns Hopkins Kimmel Cancer Center shows that a newly identified form of lymph node-like structures found in liver tumors after treatment with immune checkpoint inhibitors (ICIs) in advance of surgery may be important markers of treatment response and long-term patient outcomes. The research, published…

A study led by Massachusetts General Hospital (MGH) shows women with hepatocellular carcinoma are less likely to receive a liver transplant than men with the same condition. Women with this kind of cancer were also more likely to die or be taken off the organ transplant list due to health…

Surgical resection for hepatocellular carcinoma (HCC), one of the forms of liver cancer, is typically reserved only for those patients with single tumors without vascular invasion, but new research from a retrospective study by investigators at the Johns Hopkins shows that neoadjuvant immunotherapy could allow high-risk HCC patients, including those…

Researchers have discovered a new drug delivery mechanism for targeting the oncogenic fusion protein responsible for development of fibrolamellar hepatocellular carcinoma (FLC), an aggressive form of pediatric liver cancer. The therapy involves targeting the mRNA of the fusion protein using a small interfering RNA (siRNA). As described in Molecular Therapy,  researchers at Rockefeller…

Scientists at the University of Geneva (UNIGE) and Geneva University Hospitals (HUG) have shed light on the far-reaching consequences of maternal obesity, particularly its role in predisposing unborn children to liver diseases and potentially liver cancer. Obesity, an epidemic looming large in many developed nations, not only poses a significant…

A new study reveals that the mechanical property of elevated viscoelasticity correlates with increased risk of liver cancer, particularly in people with type 2 diabetes. These results suggest that this easily measured biophysical property can identify type 2 diabetics at increased risk for liver cancer who do not meet current…

A trio of immune cells are key to immunotherapy response in hepatocellular carcinoma (HCC), according to new work from the Icahn School of Medicine at Mount Sinai. The research team found that interaction between mature dendritic cells, CXCL13+ T follicular-helper-like cells, and progenitor CD8 T cells helps to maintain a…

Scientists at the German Cancer Research Center (DKFZ) sought to determine the role of gastrointestinal B cells in the development of nonalcoholic steatohepatitis (NASH), fibrosis, and NASH-induced HCC. They discovered B cells promote liver cancer with a dual strategy. Their findings are published in the Journal of Hepatology. “Worldwide, fatty…

Scientists at the Princess Máxima Center for pediatric oncology and Hubrecht Institute in the Netherlands report organoids and CRISPR-Cas9 allowed them to better understand the tumor biology and biological consequences of different DNA changes of fibrolamellar carcinoma (FLC), a rare type of childhood liver cancer. The findings are published in Nature…

Research led by Tsinghua University, Beijing, has developed a deep learning (DL) program that can improve prognostic biomarker discovery to help patients with liver cancer. The researchers used the tool, known as PathFinder, to show the value of a biomarker that plays a key role in liver cancer outcomes. They…

Auransa Inc. and the University of Southern California (USC) are collaborating on a Phase I clinical trial to evaluate AU409, a new kind of treatment for cancers of the liver and solid tumors with liver dominant disease. In preclinical studies, the compound showed anticancer activity against hepatocellular carcinoma (HCC). “AU409…

A new study reveals that circadian clock proteins are actively involved in the development of hepatocellular carcinoma (HCC) and provide a mechanistic explanation for how liver cancer cells use these proteins to grow. The research, published in the journal Proceedings of the National Academy of Sciences, also found that inhibiting…

Dr. Maria Reig, head of the Barcelona Clinic Liver Cancer (BCLC) Unit at Hospital Clinic Barcelona has developed an experimental drug that inhibits an enzyme playing a crucial role in cell division and growth. The drug, NMS-01940153E, has shown signs of anti-cancer activity with manageable side effects in liver cancer…

A study in mice by scientists from the German Cancer Research Center and Hebrew University in Jerusalem reveals a new driver of liver cancer. The findings are published in the Journal of Hepatology. The team of researchers conducted their studies in mice that were genetically modified to develop chronic liver…

Hepatocellular carcinoma (HCC) modifies its metabolism in a way that leaves it susceptible to disruptions in the supply of a key molecule, arginine. Researchers at the Perelman School of Medicine at the University of Pennsylvania have developed an approach in mice that left HCC tumors in a senescent state. Their…